PARIS, 04-Jan-2017 — /EuropaWire/ — Sanofi announced today that Soliqua™ 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by prescription in U.S. pharmacies. Soliqua 100/33 is indicated for the treatment of adults with type 2 … Read the full press release
Both companies will become global leaders in two different sectors of the pharmaceutical market Paris (France) and Ingelheim (Germany), 03-Jan-2017 — /EuropaWire/ — Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an … Read the full press release
PARIS, 03-Jan-2017 — /EuropaWire/ — Sanofi and its vaccines global business unit Sanofi Pasteur confirmed today the end of their vaccine joint-venture with MSD (known as Merck & Co. Inc., in the United States and Canada), Sanofi Pasteur MSD (SPMSD). … Read the full press release
Posted in Business, France, Healthcare, Pharma & Biotech
Tagged Merck & Co. Inc., MSD, Sanofi, Sanofi Pasteur, vaccine joint-venture
PARIS, 04-Oct-2016 — /EuropaWire/ — Sanofi today announced the appointment of Alan Main as Executive Vice President Consumer HealthCare, effective October 1st, 2016. Mr. Main will be a member of the Executive Committee and lead a newly created Consumer Healthcare … Read the full press release
Posted in Business, France, Healthcare, Management, Pharma & Biotech
Tagged Alan Main, Consumer HealthCare, Olivier Brandicourt, Sanofi
PARIS, 31-Mar-2016 — /EuropaWire/ — Sanofi announced today the appointment of Dr. Yong-Jun Liu as Head of Research, Global R&D, effective April 1, 2016. He will report to Dr. Elias Zerhouni, President, Global R&D. Dr. Liu is one of the world’s … Read the full press release
Posted in France, Management, Pharma & Biotech
Global introduction of the first Dengue Vaccine gains further momentum with this third approval in a row in an endemic country – With 1.4 million dengue cases reported this year, Brazil stands to gain tremendous value from this new dengue … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged Dengue, Dengue Vaccine, Dengvaxia®, Sanofi, Sanofi Pasteur
LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone PARIS, 14-9-2015 — /EuropaWire/ — Sanofi announced today that the LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Science
Tagged glargine, insulin, LixiLan-L Phase III clinical trial, metformi, Sanofi, type 2 diabetes
Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa®(vandetanib) from AstraZeneca Paris, France, 30-7-2015 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that it has entered into a definitive agreement with AstraZeneca to acquire Caprelsa® (vandetanib), a … Read the full press release
Posted in Business, France, Healthcare, Management, Pharma & Biotech
Tagged AstraZeneca, Caprelsa® (vandetanib), Genzyme, Luke Miels, Sanofi
Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration Companies agree to jointly advance PD-1 and other new immuno-oncology antibodies – Sanofi commits to an initial investment of up to $2.17 billion in the exclusive collaboration, including $640 million in upfront payments to Regeneron … Read the full press release
Investigational Enzyme Replacement Therapy to Treat Non-Neurological Manifestations which characterize Niemann-Pick Type B PARIS, 5-6-2015 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olipudase alfa. … Read the full press release
Posted in France, Pharma & Biotech, Science
Tagged Breakthrough Therapy, Genzyme, Niemann-Pick Type B, olipudase alfa, Richard Peters, Sanofi, sphingomyelin, US FDA
PARIS, 9-3-2015 — /EuropaWire/ — Sanofi today announced the appointment of Robert Castaigne as Chairman of its Audit Committee. Mr. Castaigne succeeds Dr. Klaus Pohle who has chaired Sanofi’s Audit Committee since 2004. This appointment is effective as of the Sanofi Board … Read the full press release
Posted in Business, France, Healthcare, Management, Pharma & Biotech
Tagged Dr. Klaus Pohle, global healthcare leader, Robert Castaigne, Sanofi
Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows Global Approvals PARIS, 17-11-2014 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has approved LemtradaTM (alemtuzumab) for … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged David Meeker, Dr. Timothy Coetzee, Edward Fox, FDA, Genzyme, LemtradaTM (alemtuzumab), M.D., multiple sclerosis (MS), Ph.D., Sanofi
Up to $200 Million Collaboration to Support Pioneering Science and New Treatments Paris and South San Francisco, CA, 18-9-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and MyoKardia, Inc., a privately-held company leading the development of precision therapies for genetic … Read the full press release
In approximately 70 percent of patients, disability scores improved or remained stable for an additional two years beyond the two-year pivotal multiple sclerosis studies Approximately 70 percent of patients treated with Lemtrada did not receive a third course of treatment … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged Genzyme, Lemtrada™ (alemtuzumab) for multiple sclerosis, Sanofi
Only First-Line Oral Treatment for Adult Gaucher Disease Type 1 Paris, 22-8-2014 — /EuropaWire/ — Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has approved Cerdelga™ (eliglustat) capsules, the only … Read the full press release
First shipment marks a critical step in improving access to treatment worldwide Paris, France, and South San Francisco, United States, 19-8-2014 — /EuropaWire/ — Sanofi (Euronext: SAN and NYSE: SNY) and PATH today announced the delivery of the first large-scale batches of … Read the full press release
Initial focus on insulin-device combinations and care management services Paris and Minneapolis, Minn., 16-6-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and Medtronic, Inc. (NYSE: MDT) today announced that they have signed a memorandum of understanding to enter into a … Read the full press release
Posted in Business, France, Healthcare, Pharma & Biotech, Society
Tagged d Pascale Witz, Diabetes, Medtronic, Omar Ishrak, Sanofi
Both doses of investigational drug sarilumab met all three co-primary endpoints New data include major clinical response rates and ACR20 scores at 52 weeks Paris and Tarrytown, NY, 16-6-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, … Read the full press release
Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases in risk of low blood sugar events of up to 31% at night-time compared with Lantus® All studies in the phase 3 “EDITION” clinical trial program, including a … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged fewer low blood sugar events, Geremia Bolli, Lantus®, Sanofi, Toujeo® consistently
Shan5™ is the first vaccine jointly developed by the Indian company and its parent company Sanofi Pasteur WHO’s decision allows for the purchase of Shan5™ by United Nations agencies Lyon, France, 7-5-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?